Charles Zollinger
General Practice · Rexburg, IDNPI 1629182282
Payments from drug & device makers
Across 97 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$509
- Amgen$272
- Johnson & Johnson$148
- Ultragenyx Pharmaceutical Inc.$77
- Novo Nordisk$66
- Lilly USA, LLC$55
- plus $461 from 20 others
What the payments were for
- Food & beverage$1,588100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $509 |
| Amgen | 15 | $272 |
| Johnson & Johnson | 10 | $148 |
| Ultragenyx Pharmaceutical Inc. | 4 | $77 |
| Novo Nordisk | 5 | $66 |
| Lilly USA, LLC | 4 | $55 |
| AstraZeneca | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Pfizer | 2 | $32 |
| Novartis | 2 | $29 |
| Flowonix Medical Incorporated | 1 | $27 |
| Abbott | 2 | $27 |
| Eisai Inc. | 1 | $25 |
| Boston Scientific | 2 | $25 |
| Bayer | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| GSK | 1 | $13 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$1,588 in reported general payments places this provider in the 80th percentile of 581 general practice providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $12,418 |
| OzempicSemaglutide | 12 | $11,276 |
| FarxigaDapagliflozin Propanediol | 12 | $8,973 |
| HumalogInsulin Lispro | 11 | $3,679 |
| NovologInsulin Aspart | 21 | $2,409 |
| Felbamate | 11 | $1,914 |
| Nebivolol Hcl | 29 | $1,318 |
| Levothyroxine Sodium | 114 | $1,194 |
| Tamsulosin Hcl | 61 | $861 |
| Omeprazole | 87 | $689 |
| Pantoprazole Sodium | 44 | $652 |
| Atorvastatin Calcium | 50 | $557 |
| Lansoprazole | 16 | $478 |
| Losartan Potassium | 68 | $468 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 60 | $462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $66 | $13,68533 claims |
| PfizerEliquis | $32 | $12,41814 claims |
| AstraZenecaFarxiga | $43 | $8,97312 claims |
| Lilly USA, LLCHumalog | $55 | $3,67911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 581 general practice providers in Idaho.
Other general practice in Rexburg
- Warren WillisEmmett$11.4M
- Wade PillingMeridian$1.1M
- Erin ElliottPost Falls$74K
- Jamison SpencerBoise$35K
- Michelle FreshwaterMeridian$18K
- Brooke FukuokaTwin Falls$16K
- Ty CorbridgeSandpoint$10K
- Eric GoettscheMeridian$10K
- Brian CrawfordPocatello$8K
- Erin LeavittLewiston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.